Months after 23andMe CEO Anne Wojcicki publicly stated she wants to take the company she co-founded private, all of the company’s independent board directors have resigned. The board letter to Wojcicki stated that its members preferred resigning over continuing to have a difference of view over the direction of the company.
A much diminished 23andMe exists today, a far cry from the phenomenon that it was in the world consumer DNA testing. Could things have unfolded differently under a different leader with a different vision?
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The company plans to pair its direct-to-consumer genetic testing with Lemonaid’s online coaching and prescription delivery. It plans to buy the company for $400 million in stock and cash.
DNA testing company 23andMe raised $82.5 million in funding, according to a recent filing. Earlier this year, decreased sales of tests kits led to cuts at the company and its competitors.
The DNA testing company confirmed on Thursday that it would lay off about 100 employees. The restructuring was a result of slowing consumer demand.
On the company's LunaDNA platform, a whole genome can be exchanged for 300 company shares, while 20 days of fitness data is equal to two shares.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
CEO and founder Julia Cheek started EverlyWell after her own experiences trying to diagnose her own health issues highlighted problems of cost and convenience in the traditional lab testing process.
Helix is responsible for sequencing the user's DNA and passing results to PerkinElmer, which will provide data analysis and interpretative services using the company's team of medical geneticists.
In contrast to 23andMe's previous FDA approvals for genetic risk tests for conditions like Alzheimer's, the diabetes assessment did not go through the FDA clearance pathway because it was characterized as a wellness product not intended to make diagnoses and provide medical advice.
The company used its previous authorization for breast cancer genetic screening as a predicate for its 510(k) approval.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
The test, which the company will sell directly to consumers, is designed to find whether patients metabolize drugs quickly or slowly.
Helix, based near San Francisco, touts its API-based business model as a way to stand out among the plethora of personal genomics companies.
In 2018 alone, ten companies have inked mega-deals of more than $100 million including Livongo, 23andMe and American Well.
Shocker, shocker — healthcare is challenging. At HLTH, CEOs Anne Wojcicki, Jonathan Bush and Frank Williams discussed how they persevered and made their companies succeed in a difficult sector.
The Food and Drug Administration has granted 23andMe the first-ever authorization for direct-to-consumer genetic testing for cancer risk without a prescription.